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A new, simple, fast, reproducible and sensitive reversed phase HPLC method, using a new stationary 
phase containing embedded urea polar groups, has been developed and validated for the simultaneous 
determination of clobutinol hydrochloride (CLO) and doxylamine succinate (DOX) in syrups. The 
determination was carried out on a C8 urea column (125 mm x 3.9 mm i.d., 5 mm particle size) synthetized 
at the Liquid Chomatography Laboratory (LabCrom) of the Chemistry Institute of Unicamp. The mobile 
phase consisted of a mixture of acetonitrile:methanol:phosphate buffer (pH 2.5) in the gradient mode. 
The diode array detector (DAD) was operated at 230 nm for CLO and 262 nm for DOX. The method 
showed adequate precision, with relative standard deviations (RSD) less than 1%. The presence of the 
excipients did not interfere in the results of the analysis. Accuracy was determined by adding standards 
of the drugs to a placebo and good recovery values were obtained. The analytical curves were linear 
(r2 0.9999 for CLO and 0.9998 for DOX) over a wide concentration range (2.4-336 μg mL-1 for CLO 
and 2.3-63 μg mL-1 for DOX). The solutions were stable for at least 72 hours at room temperature. The 
criteria for validation using the ICH guidelines were fulfilled.
Uniterms: Clobutinol hydrochloride/determination. Doxylamine succinate/determination. High 
performance liquid chromatogralhy/quantitative analysis. 
Um novo método simples, fácil e reprodutível, de fase reversa para CLAE, usando uma fase estacionária 
contendo um grupo polar, uréia, embutido, foi desenvolvido e validado para determinação simultânea 
de cloridrato de clobutinol (CLO) e succinato de doxilamina (DOX) em xarope. A determinação foi 
realizada em uma coluna C8 uréia (125 mm x 3,9 mm d.i., 5 mm tamanho de partícula) sintetizada em 
nosso laboratório (LabCrom). A fase móvel consistiu de mistura de acetonitrila:metanol:tampão fosfato 
pH 2,5, em eluição por gradiente. O detector por arranjos de diodo (DAD) foi utilizado a 230 nm para 
CLO e a 262 nm para DOX. O método apresentou precisão adequada, com desvio padrão relativo menor 
que 1%. A presença de excipientes não interferiu nos resultados obtidos. A exatidão foi realizada pela 
adição dos padrões dos fármacos ao placebo e valores de recuperação aceitáveis foram obtidos. As 
curvas analíticas mostraram-se lineares (r2 0,9999 para CLO e 0,9998 para DOX) em uma ampla faixa 
de concentração (2,4-336 μg mL-1 para CLO e 2,3-63 μg mL-1 para DOX). A solução padrão foi estável 
por 72 horas a temperatura ambiente. Os parâmetros de validação foram realizados conforme o guia ICH.
Unitermos: Cloridrato de clobutinol/determinação. Succinato de doxilamina/determinação. Cromatografia 
líquida de alta eficiência/análise quantitativa. 
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INTRODUCTION
C l o b u t i n o l  h y d r o c h l o r i d e ,  ( C L O ) , 
2-(4-chlorobenzyl)-3-(dimethylaminomethyl)butan-2-ol 
hydrochloride, is widely used as a centrally acting cough 
suppressant for non-productive cough (Martindale, 1996; 
USP 31, 2008). It is effective and safe, at the recom-
mended daily dose, for coughs from cancer, including 
advanced cancer cough (Homsi et al., 2001). Clobutinol 
hydrochloride is not cited in any pharmacopoeia and a 
literature survey reveals that the number of the analytical 
methods referring to the drug is relatively limited. The 
drug has been determined in biological fluids by gas 
chromatography using surface ionization detection (Ishi 
et al., 1993). Derivative UV spectrophotometric and high 
performance liquid chromatographic (HPLC) methods 
have also been reported (Malliou et al., 2002). Recently, 
a HPLC method to determine this drug together with some 
anti-inflammatory drugs in urine has been described (Mal-
liou et al., 2004). A potentiometric ion-selective electrode 
method based on clobutinol-tetraphenyl borate has also 
been reported (Issa, Zayed, 2006).
Doxylamine succinate, (DOX), chemically N,N-
dimethyl-2-[-methyl-(2pyridyl)benzyloxy]ethylamine 
hydrogen succinate, is an antihistaminic with antimusca-
rinic and pronounced sedative effects. It is used for treat-
ing nausea during pregnancy and it is present in over the 
counter cold and sedative pharmaceuticals (Sthal, 1998). 
Some chromatographic methods have been proposed for 
its determination at trace levels (Argekar, Sawant, 1999; 
Argekar, Sawant, 2005), mass spectrometry (Hansen et 
al., 1985), capillary electrophoresis (Tang et al., 2000), 
UV spectrometry in a micellar medium (Monferrer-Pons 
et al., 1996) and Fourier transform infrared spectroscopy 
(FTIR) (Ventura-Gayete et al., 2006) have also been used. 
Simultaneous determination of DOX in combination with 
carbinoxamine maleate by spectrophotometry (Monferrer-
Pons at al., 1996), in combination with dextromethorphan 
hydrobromide by HPTLC (Indrayanto, 1996), in combi-
nation with pseudoephedrine hydrochloride and dextro-
methorphan hydrobromide by HPLC (Fong, Eickhoff, 
1989), and in combination with pyridoxine hydrochloride 
by HPLC (Argekar, Sawant, 2005) have been reported 
in the literature. Simultaneous determination of DOX in 
combination with other antihistamines in pharmaceutical 
preparations by liquid chromatography with a micelar 
mobile phase of sodium dodecyl sulfate and pentanol 
(Paciolla et al., 2001; Gil-Augusti et al., 2001A), of DOX 
in combination with phenethylamine-antihistamine using 
C8, C18 or cyano columns with a micellar sodium dodecyl 
sulfate-pentanol mobile phase (Gil-Augusti et al., 2001B), 
and of DOX in combination with phenylpropanolamine 
hydrochloride, chlorpheniramine maleate, dextrometho-
rphan hydrobromide, paracetamol and gaifenesin using 
ion pair reversed-phase by HPLC, have also been reported.
The simultaneous determination of CLO and DOX 
by HPLC has not been reported. The objective of this study 
is to develop a new, simple and fast analytical method us-
ing HPLC to quantify CLO and DOX in syrup, followed 
by a validation study.
EXPERIMENTAL
Material and reagents
Clobutinol hydrochloride and doxylamine succinate 
(Figure 1) were obtained from Forchemic d’Heuman Phar-
ma GMBA (Germany). The standards of CLO and DOX 
were purchased from United States Pharmacopeia (USP). 
Potassium dihydrogen phosphate was obtained from J. T. 
Baker (Eldorado de Mexico, Mexico). Orthophosphoric 
acid was obtained from Mallinckrodt (Phillipsburg, USA). 
HPLC grade acetonitrile and methanol were purchased 
from J.T. Baker (Phillipsburg, USA). Water was deionized 
and purified by means of a Milipore Milli-Q (Bedford, MA 
USA). 0.45 mm nylon filters were obtained from Millipore. 
Syrups having clobutinol hydrochloride in combination 
with doxylamine succinate were purchased on the Bra-
zilian market. A placebo, for the validation study, was 
prepared with the declared excipients, to verify possible 
interferences. These were: hydroxyethylcellulose, sodium 
saccaride, sodium benzoate, sorbitol, water, flavor and 
glycerol.
Chromatographic instrument and conditions
The HPLC system used to develop this technique was 
a Merck-Hitachi Elite LaChrom consisting of a quaternary 
pump (L-7130), degasser, column oven (L-2300) and au-
tomatic injector (L-2200). Quantification and peak purity 
were checked with a diode array detector (L-2450). Data 
acquisition was performed using the chromatography soft-
ware package EZCHrom Elite, version 3.1.3. The pH meter 
(model 744) was from Metrohm (Herisau-Switzerland).
FIGURE 1 - Chemical structures of (A) clobutinol hydrochloride 
and (B) doxylamine succinate.
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The chromatographic separations of CLO and DOX 
were performed using a 125 mm x 3.9 mm i.d. column 
packed with a C8 urea stationary phase containing an 
embedded urea (polar) group prepared in our laboratory 
by a modification of the procedure from preparation of sta-
tionary phases with polar groups (Silva et al., 2001, 2002, 
2003). The injection volume to carry out the chromatog-
raphy was set at 5 mL. The chromatographic parameters: 
retention factor (k), plate number (N), resolution (RS) and 
tailing factor (TF) were calculated to evaluate the separa-
tion. The detector wavelengths were at 262 nm for DOX 
and 230 nm for CLO.
· Mobile phase
The mobile phase used in this study consisted 
of a mixture of acetonitrile:methanol:phosphate buf-
fer (pH 2.5) in the gradient mode, as shown in Table I. 
The pH 2.5 phosphate buffer solution was prepared by 
dissolving 340 mg of potassium monobasic phosphate 
in 1000 mL of water; the pH was adjusted to 2.5 with 
10% v/v orthophosphoric acid. The solvents and buffer 
were filtered through a 0.45 mm GH-membrane filter and 
degassed ultrasonically prior to use. The temperature of 
the column was held at 25 °C.
Preparation of solutions
· Standard stock solutions
A standard stock solution of DOX was prepared 
by accurately weighing 45.0 mg of the DOX standard, 
dissolving it in water and diluting to 100.0 mL in a volu-
metric flask (0.45 mg mL-1). A standard stock solution of 
CLO was prepared by accurately weighing 48.0 mg of the 
standard of CLO, dissolving it in 5.0 mL of acetonitrile 
and diluting it with water in a 100.0 mL volumetric flask 
(0.48 mg mL-1).
TABLE I - Gradient used in separation of CLO and DOX
Time 
(min)
Buffer 
(%)
MeOH 
(%)
ACN 
(%)
Flow rate 
(mL min-1)
0 77 0 23 1.5
5.0 77 0 23 1.5
8.0 71 2 27 2.0
12.5 71 2 27 2.0
13.5 71 2 27 3.0
14.0 71 2 27 3.0
15.0 77 0 23 2.0
17.0 77 0 23 1.5
·  Working solution
A 1.0 mL volume of the stock solution prepared for 
DOX and a 5.0 mL volume of the stock solution of CLO 
were transferred to 10.0 mL volumetric flasks. The work-
ing solutions were diluted to volume with mobile phase to 
obtain 45 μg mL-1 of DOX and 240.0 μg mL-1 of CLO. An 
aliquot was taken and filtered through a PVDF membrane 
filter (0.45 mm), before injection. For the calibration solu-
tions, aliquots of the standard stock solutions of CLO and 
DOX were taken in different volumetric flasks and diluted 
with mobile phase to obtain final concentrations in the 
range 2.4-336.0 μg mL-1 for CLO and 2.3-63.0 μg mL-1, 
for DOX.
· Sample solutions
A 6.0 mL volume of sample was transferred to a 
100.0 mL volumetric flask, 50.0 mL of mobile phase was 
added and the solution was stirred for 10 minutes. After 
that the solution was diluted to volume with mobile phase. 
Appropriate proportions were taken and filtered through a 
PVDF membrane filter (0.45 mm) and used for the assays. 
To verify possible interferences, a placebo was prepared 
with all of excipients of the syrup and a solution was ob-
tained from dilution of the placebo in mobile phase using 
the same dilution and procedures used for the preparing 
sample solution. Each of the solutions prepared were in-
jected in triplicate into the chromatographic system.
Validation of method
Validation of an analytical method must demonstrate 
that it fulfills all the requirements of the analytical applica-
tion, ensuring the reliability of the results. The validation 
was carried out by studying the parameters specificity, 
linearity, precision, sensitivity, accuracy, solution stabil-
ity and limits of detection and quantification adequate for 
the analysis (ANVISA, 2003; ICH, 1995A; ICH, 1995B; 
INMETRO 2007).
System suitability
For system suitability studies, five replicate injec-
tions of the mixed standard solution were made, and 
parameters such as RSD of the peak area, column effi-
ciency, resolution and the tailing factor of the peaks were 
calculated.
Specificity
The specificity of the method was investigated by 
analyzing chromatograms obtained from the placebo, 
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mobile phase, standard and sample solutions and compar-
ing the retention times of components of the samples to 
be analyzed with standards of CLO and DOX. The peak 
purity of CLO and DOX in the sample and in the standard 
preparation was also verified by comparisons of the spectra 
obtained with the diode array detector.
Calibration and linearity
The linearity of the method was tested in the range 
of 5-140% of the target level of the assay concentration of 
DOX (45 μg mL-1) and from 1-140 % of the target level 
of the assay concentration of CLO (240 μg mL-1). Mixed 
standard solutions containing 2.3-63.0 μg mL-1 of DOX 
and 2.4-336.0 μg mL-1 of CLO at each linearity point 
were prepared. The intervals used for linearity was 2.3, 
9.0, 18.0, 27.0, 36.0, 45.0, 54.0 and 63.0 μg mL-1 of DOX 
and 2.4, 24.0, 96.0, 144.0, 192.0, 240.0, 264.0 and 336.0 
μg mL-1 of CLO. Each of the levels of concentration was 
injected in triplicate. In simultaneous determinations, the 
peak area versus concentration data were performed by 
linear least-squares regression analysis and the analytical 
curves were found to be linear for both analytes in the 
mentioned concentrations.
Detection limit and quantitation limit
The LOD and LOQ were determined based on 
signal-to-noise ratios of the analytical responses at 3 and 
10 times the background noise, respectively.
Precision
The precision was evaluated by intraday (repeat-
ability) and interday (intermediate precision) studies. The 
intraday precision was investigated using six different 
sample solutions prepared from a syrup at 100% of the 
target level for both the analytes. Each solution was in-
jected in triplicate and the peak areas obtained were used 
to calculate mean and RSD values of each ingredient. The 
interday precision was checked by preparing, and analyz-
ing in triplicate, six different sample solutions from the 
syrup at the same concentration levels as used for intraday 
precision, on different days, by different analysts and/or 
different HPLC systems (ANVISA, 2003). The percent 
of the assay for the two components was calculated using 
the analytical curve.
Accuracy
The accuracy of the method was evaluated by 
recovery experiments. The recovery experiments were 
performed by fortifying the excipient mixture with three 
known concentrations of the drugs, at the levels of 80%, 
100% and 120% of the target concentrations (45 μg mL-1 
of DOX and 240 μg mL-1 of CLO). Three samples were 
prepared for each recovery level. The amount of DOX and 
CLO recovered were calculated in relation to the added 
amount. Each solution was injected in triplicate and peak 
areas were used to calculate the mean and % RSD values.
Robustness
A study of robustness was carried out by testing the 
susceptibility of the measurements to deliberate varia-
tions of the analytical conditions. The factors chosen for 
this study were the temperature (°C), pH, flow rate (mL 
min−1), mobile phase (percentage of acetonitrile), injection 
volume (µL), different columns dimensions.
Solution stability
To determine the stability of the standard and sample 
solutions of CLO and DOX, the assay method was car-
ried out after leaving the test solutions of both sample 
and reference in tightly capped volumetric flasks at room 
temperature for 72 h. The sample solutions were assayed 
at 6 h intervals throughout the study period. Mobile phase 
stability was also analyzed by assaying the freshly pre-
pared sample solutions against freshly prepared reference 
standard solutions at 6 h intervals up to 72 h. Mobile phase 
was kept constant during the study period.
Stability-indicating ability
A stability study is an integral part of pharmaceuti-
cal product development (ICH, 2006). The data collected 
during a stability study determine the shelf life, storage 
conditions and impurity profile of the product. If the as-
say method itself indicates stability, it is considered to be 
versatile. Therefore, an attempt was made to investigate 
the stability-indicating ability of the proposed method. 
Sample solutions containing 4.0 mg mL-1 of CLO and 
0.75 mg mL-1 of DOX, equivalent to the concentrations 
found in syrups, were kept at 80 ºC; or with 1 mL of 
0.1 mol L-1 HCl; or 1 mL of 0.1 mol L-1 NaOH; or 1 mL 
of 10% H2O2 added or in the presence of UV light, each 
for 24 hours. Simultaneosly, 4.0 mg of CLO and 0.75 mg 
of DOX in syrup, and a mixture of 4.0 mg of CLO and 
0.75 mg of DOX standards were exposed to the same stress 
conditions. All the exposed standards and syrup samples 
then were analyzed by the validated method.
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RESULTS AND DISCUSSION
Optimization of the chromatographic conditions
The organic solvents acetonitrile and methanol have 
different effects on the solvation of the analytes and there-
fore they also affect the symmetry and selectivity of the 
peaks (Argekar, Sawant, 2005). The best chromatographic 
condition was obtained with a mobile phase containing a 
mixture of 27% acetonitrile, 2% methanol and 71% buf-
fer; this condition provided the best resolution of CLO 
and DOX. 
Variations of the buffer concentration helped to 
achieve a longer retention time for DOX. A decrease in 
ionic strength leads to an increase in retention for DOX 
(Pacciolla et al., 2001). A concentration of 0.025 mol L-1 
KH2PO4 was the optimum concentration for the separation. 
A concentration less than 0.020 mol L-1 KH2PO4 increased 
the retention of DOX and a concentration exceeding 
0.030 mol L-1 KH2PO4 resulted in decreased resolution 
between DOX, CLO and the earlier eluting excipients.
The retention times were also affected by variation 
of the pH of the mobile phase. In the pH range 4.0-5.5 
no changes in retention for DOX were observed. At 
pH 2.5-4.0 several changes were observed. DOX is ca-
pable of being protonated twice, with reported pKa values 
of 4.0 (pyridinium group) and 9.2 (tertiary amine group). 
The rapid increases in retentions as the pH are due to large 
concentration of the dication it forms (Sa´sa et al., 1987). A 
buffer of pH 2.5 was chosen since provides baseline sepa-
ration with sharp peaks and reasonable retention times.
The good separation between CLO, DOX and the 
excipients is due to the new stationary phase with embed-
ded polar groups, which shows different selectivities and 
retentions for basic and polar compounds. This effect can 
be attributed to the weakening of the interaction between 
basic analytes and residual silanol groups on the silica 
surface (Ascah et al., 1996; O´Gara et al., 2001). Some 
mechanisms that have been proposed are the interaction 
of the polar function with the unwanted silanols through 
hydrogen bonding and an increase in the water concen-
tration on the surface because of the hydrogen bonding 
ability of the polar groups. As a result, the surface layer 
should have a higher dielectric constant, weakening the 
interactions between residual surface silanols and basic 
analytes (Silva et al., 2002). Another advantage is that the 
phase containing embedded polar groups requires a mobile 
phase with a lower concentration of organic solvent (Silva 
et al., 2001).
The wavelengths of 263 nm and 230 nm were se-
lected for the UV detection because at these wavelengths 
there was maximum absorption in the spectra of DOX and 
CLO, respectively.
Validation of Method
System suitability
Results of system suitability parameters are shown 
in Table II.
Specificity
Figure 2 shows chromatograms of standard and 
sample solutions. The placebo solution afforded three 
peaks, also observed in the sample solutions, with low 
retention times with no potential to interfere with the CLO 
and DOX peaks. In the chromatogram of mobile phase no 
interference was observed. The retention times of CLO and 
DOX were similar in the chromatograms of the standard 
and sample solutions.
The peak purities for CLO and DOX were 0.9993 
and 0.9991, respectively, showing that the analyte peaks 
are pure, without the interference of analog compounds 
and also that the formulation excipients do not interfer 
with the analyte peaks.
Calibration and linearity
The correlation coefficients, linearity range and 
percent RSD of concentration/area ratio of the analytical 
curves were calculated and are in Table III.
Detection limit and quantitation limit
The LOD and LOQ are 0.65 μg mL-1 and 2.4 μg mL-1 
for CLO and 0.62 μg mL-1 and 2.3 μg mL-1 for DOX, re-
spectively.
TABLE II - System Suitability Parameters
Parameters Clobutinol 
hydrochloride
Doxylamine 
succinate
Plate Number 13514 8964
Retention Time (min) 13.7 7.0
Retention Factor* 10.4 4.8
Resolution 17.3 ----
Tailing Factor (5%) 1.2 1.1
% RSD peak area 0.39 0.45
* tM determined using uracil.
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Precision
The assay results and % RSD, calculated from the 
peak areas and shown in Table IV, indicate that the method 
is reliable.
Accuracy
The recovery values for CLO and DOX ranged from 
98.4% to 100.2% and 98.8% to 99.2%, respectively. The 
average recovery of the three levels (nine determinations) 
for DOX and CLO were 99.0% and 99.3%, respectively. 
The results are shown in Table V.
Robustness
The results are shown in Table VI. To exemplify 
the use of the method, a comparation with a X-Terra C8, 
150 x 4.6 mm i.d., 5 µm particle size column from Waters 
was carried out. The results obtained from analysis with 
the commercial column were similar to the chromato-
graphic separation from the C8 stationary phase containing 
an embedded urea polar group.
Solution stability
The percent RSD for the assay values determined up 
TABLE III – Range of linearity, correlation coefficient and RSD of analytical curves
Ingredients Linearity Range (μg mL-1) Correlation coefficient Concentration/area ratio (% RSD)
Clobutinol 2.4 - 336.0 0.99990 0.00151 - 0.8
Doxylamine succinate 2.3 - 63.0 0.99985 0.000033 - 0.6
FIGURE 2 - Chromatograms of standard (A) and sample (B) of (1) doxylamine succinate and (2) clobutinol hydrochloride; * excipients. 
Chromatographic conditions: stationary phase: 5µm Si-C8-urea; column: 125 mm x 3.9 mm; mobile phase: gradient of MeOH:ACN: 
KH2PO4 buffer (pH 2.5); injection volume: 5 mL; temperature: 25 °C; detection: 262 nm for DOX and 230 nm for CLO.
TABLE IV - Precision study and assay results of active ingredients in syrup
Precision Ingredients (% RSD) Label value 
(mg mL-1)
Found 
(mg mL-1)*
% Label claim
Repeatability CLO 0.45 4.0 3.97 99.3
DOX 0.63 0.75 0.77 102.7
Intermediate precision CLO 0.96 4.0 3.95 98.8
DOX 0.85 0.75 0.76 101.3
* average of six analyses. 
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TABLE V - Accuracy: recovery studies
Fortification level 
(%)
Ingredients Amount added 
(mg)
Amount found 
(mg)
Recovery 
(%)
RSD % 
(n = 3)
Average 
Recovery*
80 CLO 3.2 3.16 98.4 0.4
DOX 0.60 0.59 98.8 0.5
100 CLO 4.0 3.97 99.2 0.3 99.3
DOX 0.75 0.74 99.1 0.4 99.0
120 CLO 4.8 4.81 100.2 0.6
DOX 0.90 0.89 99.2 0.7
*Average recovery: the average of the three levels, nine determinations.
TABLE VI - Effect of HPLC experimental parameters on the 
analysis of CLO and DOX in syrups using Si-C8-urea stationary 
phase
Parameter Variation
Recovery (%) / RSD (%)
CLO DOX
Temperature 
(°C)
27
33
98.1 / 1.3
98.5 / 0.9
99.2 / 0.4
99.0 / 0.6
pH 2.3
2.7
98.7 / 0.7
98.9 / 0.8
98.8 / 0.4
99.1 / 0.3
Flow rate 
(mL min-1)
1.5; 2.1; 3.1
1.4; 1.9; 2.9
98.8 / 1.1
98.5 / 1.2
100.2 / 0.5
99.5 / 0.7
Amount of 
acetonitrile (%)
> 5%
< 5%
99.1 / 0.5
98.9 / 0.6
99.7 / 0.8
99.3 / 0.4
Injection volume 
(µL)
3
7
99.1 / 0.8
99.6 / 0.5
100.7 / 0.7
100.1 / 0.3
Column length 125 mm x 3.9 mm; 
150 mm x 4.6 mm
100.1 / 0.4 
98.9 / 0.6
99.5 / 0.7 
99.6 / 0.5
TABLE VII - Assay results of samples exposed to stress conditions
Stress conditions
Amount of drug found (mg mL-1) Peak purity
RS*CLO DOX CLO DOX
Initial (unexposed sample) 4.0 0.75 0.9993 0.9991 17.3
Acid hydrolysis (0.1mol L-1 HCl-24 h) 3.9 0.73 0.9985 0.9988 16.6
Base hydrolysis (0.1 mol L-1 NaOH-24 h) 3.8 0.72 0.9974 0.9982 17.2
Oxidation (10% H2O2-24 h) 2.4 0.38 0.9915 0.9939 13.6
Heat (80 °C-24 h) 3.8 0.73 0.9956 0.9965 13.6
UV Light (25 °C-24 h) 3.9 0.71 0.9983 0.9948 16.3
* Resolution between CLO and DOX
to 72 h for the sample preparation were 0.85 for CLO and 
0.76 for DOX; in the standard preparation the values were 
0.85 for CLO and 0.76 for DOX. The assay values were 
within 2 % after 72 hours. The results indicate that the so-
lutions were stable for at least 72 h at ambient temperature.
Stability-indicating ability
In the chromatograms of samples exposed to 
heat, alkali, acid and light, no degradation peaks were 
observed, and the assay values were not changed sig-
nificantly for either ingredient. However, in the case of 
samples exposed to a strong oxidizing agent, H2O2, the 
assay values of both ingredients were found to decrease 
significantly. The peaks for CLO/DOX in the chromato-
grams of all exposed samples were investigated using the 
DAD detector and were found to be pure. These results 
are given in Table VII.
CONCLUSION
The proposed method is simple, precise, accurate 
and selective for the simultaneous determination of CLO 
and DOX in syrups. It can be easily and conveniently 
adopted for routine quality control analysis.
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